26 June 2015
EMA/CHMP/425257/2015
Procedure Management and Committees Support Division

Committee for medicinal products for human use (CHMP)

Minutes of meeting held on 18-21 May 2015

Chair: Tomas Salmonson – Vice-chair: Pierre Demolis

18 May 2015, 13:00 – 19:15, room 2A

19 May 2015, 08:30 – 19:45, room 2A

20 May 2015, 08:30 – 19:30, room 2A

21 May 2015, 08:30 – 13:00, room 2A

Note on access to documents

Some documents mentioned in the agenda/minutes cannot be released at present following a request for access to documents under Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Health & Safety Information

In accordance with the Agency's Health and Safety policy, delegates are to be briefed on health & safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in the minutes is considered commercially confidential and therefore not disclosed. With regards to therapeutic indications listed against products it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. The procedures discussed by the CHMP are on-going and therefore are considered confidential. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available. For orphan medicinal products the applicant details are published as this information is already publicly available.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

Of note, this agenda is a working document primarily designed for CHMP members and the work the Committee undertakes.

Further information with relevant explanatory notes can be found at the end of this document.

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CHMP plenary session held 18-21 May 2015. See 18-21 May 2015 CHMP minutes (to be published post June 2015 CHMP meeting).

1.2. Adoption of agenda

CHMP agenda for 18-21 May 2015.

1.3. Adoption of the minutes

CHMP minutes for 20-23 April 2015.

The CHMP adopted the minutes.

2. Oral Explanations

2.1. Pre-authorisation procedure oral explanations

2.1.1. - panobinostat – Orphan - EMEA/H/C/003725

Novartis Europharm Ltd; treatment of multiple myeloma
Scope: Oral explanation
Action: Oral explanation on Tuesday 19 May 2015 at time 11:00
List of Outstanding Issues adopted on 26.03.2015. List of Questions adopted on 25.09.2014.
Report from SAG Oncology meeting held 4 May 2015.
The Committee noted the SAG Oncology report.
An oral explanation was held on Tuesday 19 May 2015 at time 11:00, focusing on the benefit/risk in the proposed subgroups.

2.1.2. - human heterologous liver cells – Orphan / ATMP - EMEA/H/C/003750

Cytonet GmbH&Co KG; treatment of urea cycle disorders (UCD)

Scope: Oral explanation

Action: Oral explanation to be held on Wednesday 20 May 2015 at 11.00 was postponed to June.

List of Outstanding Issues adopted on 18.12.2014. List of Questions adopted on 25.04.2014.

See also 3.2.10

2.1.3. - idebenone – Orphan - EMEA/H/C/003834

Santhera Pharmaceuticals (Deutschland) GmbH; treatment of Leber's Hereditary Optic Neuropathy (LHON)
Scope: Oral explanation
Action: Oral explanation on Tuesday 19 May 2015 at 14.00.
List of Outstanding Issues adopted on 26.02.2015. List of Questions adopted on 25.09.2014.
See also 3.2.11.

2.1.4. - asfotase alfa - Orphan - EMEA/H/C/003794

Alexion Europe SAS; treatment of paediatric-onset hypophosphatasia

Scope: Oral explanation

Action: Oral explanation to be held on Wednesday 20 May 2015 at 9.00 was cancelled.

List of Outstanding Issues adopted on 26.03.2015. List of Questions adopted on 20.11.2014.

The CHMP agreed that no oral explanation was needed at this time.

See also 3.2.9

2.1.5. - dinutuximab – Orphan - EMEA/H/C/002800

United Therapeutics Europe Ltd; treatment of neuroblastoma, treatment of high-risk neuroblastoma

Scope: Oral explanation

Action: Possible oral explanation – was not needed this time.

List of Outstanding Issues adopted on 22.01.2015. List of Questions adopted on 25.04.2014

See 3.1.11

2.2. Re-examination procedure oral explanations

2.2.1. GVK Biosciences - - (EMEA/H/A-31/1408)

Re-examination Rapporteur: Hubert Leufkens, Re-examination Co-rapporteur: Karsten Bruins Slot

Scope: Article 31 procedure triggered by the European Commission concerning GVK Biosciences Private Limited (GVK Bio), Swarna Jayanthi commercial complex, Ameerpet, Hyderabad 500 038, India following critical GCP deficiencies reported during an inspection performed by the ANSM (Agency for Medicines and Health Products Safety, France) on 19-23 May 2014.

Action: Oral explanation – was not needed this time.

See also 10.7.1.

Opinion adopted on 22.01.2015.

2.3. Post-authorisation procedure oral explanations

2.3.1. Perjeta - pertuzumab - EMEA/H/C/002547/II/0010

Roche Registration Ltd
Rapporteur: Christian Schneider, Co-rapporteur: Daniela Melchiorri, PRAC Rapporteur: Doris Stenver;
Scope: "The MAH is submitting a type II 90 day variation application to extend the use of Perjeta in combination with trastuzumab and docetaxel as part of a neoadjuvant treatment for patients with locally advanced, inflammatory or early stage HER2-positive breast cancer suitable for neoadjuvant therapy (tumors > 2 cm in diameter).
The submission is based primarily on the results of two randomized Phase II studies, NEOSPHERE (WO20697) and TRYPHAENA (BO22280).
The Perjeta annexes have been updated in the concerned sections as outlined in the table below and in the SmPC track change version in Module 1.3.1.
The section 4.8 Undesirable effects of the SmPC (and the section 4 of the PIL accordingly) has been revised and includes now a pooled safety analysis across the studies CLEOPATRA, the pivotal study in metastatic breast cancer, and the two neoadjuvant studies NEOSPHERE and TRYPHAENA. A "Note to the Reviewer" providing further explanations on the pooled safety analysis is also included in the track change SmPC version in Module 1.3.1."
Action: Oral explanation was held on Tuesday 19 May 2015 at time 09:00.
See 5.1.6
Report from SAG Oncology meeting held on 9 March 2015.
Request for Supplementary Information adopted on 18.12.2014.
The Committee noted the SAG Oncology report.

2.4. Referral procedure oral explanations

No items

3. Initial applications

3.1. Initial applications; Opinions

3.1.1. - aripiprazole - EMEA/H/C/004008

See 3.2.13.

3.1.2. Bortezomib Accord - bortezomib - EMEA/H/C/003984

Accord Healthcare Ltd; treatment of multiple myeloma, Generic of Velcade
Scope: Opinion
Action: For adoption
Generic application (Article 10(1) of Directive No 2001/83/EC)
List of Outstanding Issues adopted on 26.03.2015. List of Questions adopted on 23.10.2014

The Committee confirmed that all issues previously identified in this application had been addressed.
The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The legal status was agreed as medicinal product subject to restricted medical prescription.
The summary of opinion was circulated for information.

3.1.3. - docetaxel - EMEA/H/C/003925

See 3.2.12.

3.1.4. Evotaz - atazanavir / cobicistat - EMEA/H/C/003904

Bristol-Myers Squibb Pharma EEIG; treatment of HIV-1 infected combination with other antiretroviral medicinal products
Scope: Opinion
Action: For adoption
Fixed combination application (Article 10b of Directive No 2001/83/EC)
List of Outstanding Issues adopted on 26.03.2015. List of Questions adopted on 20.11.2014.
The Committee confirmed that all issues previously identified in this application had been addressed.
The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The legal status was agreed as medicinal product subject to restricted medical prescription.
The summary of opinion was circulated for information.

3.1.5. - human heterologous liver cells - Orphan - ATMP - EMEA/H/C/003750

See 3.2.10 and 2.1.2.

3.1.6. Keytruda - pembrolizumab - EMEA/H/C/003820

MERCK SHARP & DOHME LIMITED; treatment of melanoma
Scope: Opinion
Action: For adoption
New active substance (Article 8(3) of Directive No 2001/83/EC)
List of Outstanding Issues adopted on 23.04.2015. List of Questions adopted on 23.10.2014.
The Committee discussed whether a full approval could be granted or whether a conditional approval was considered more appropriate and they agreed on the full approval. After going through the post authorisation measures, the Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.
Furthermore, the CHMP considered that pembrolizumab is a new active substance, as claimed by the applicant.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The legal status was agreed as medicinal product subject to medical prescription.
The Committee noted the letter of recommendation dated 20.05.2015
The summary of opinion was circulated for information.

3.1.7. Omidria - phenylephrine / ketorolac - EMEA/H/C/003702

Omeros London Limited; maintenance of mydriasis, prevention of miosis and reduction of ocular pain replacement (ILR).
Scope: Opinion
Action: For adoption
Known active substance (Article 8(3) of Directive No 2001/83/EC)
Oral explanation held on 25.09.2014. List of Outstanding Issues adopted on 25.09.2014, 22.05.2014. List of Questions adopted on 23.01.2014.
The Committee confirmed that all issues previously identified in this application had been addressed.
The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The legal status was agreed as medicinal product subject to restricted medical prescription.
The summary of opinion was circulated for information.

3.1.8. Pregabalin Zentiva - pregabalin - EMEA/H/C/003900

Zentiva, k.s.; treatment of epilepsy and Generalised Anxiety Disorder (GAD), Generic of Lyrica
Scope: Opinion
Action: For adoption
Generic application (Article 10(1) of Directive No 2001/83/EC)
List of Outstanding Issues adopted on 26.03.2015. List of Questions adopted on 18.12.2014.
The Committee confirmed that all issues previously identified in this application had been addressed.
The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The legal status was agreed as medicinal product subject to medical prescription.
The Committee noted the letter of recommendation dated 20.05.2015.
The summary of opinion was circulated for information.
Post meeting note: The amended opinion with changes to the product information was adopted via written procedure on 26 May 2015.

3.1.9. Repatha (Evolocumab Amgen Europe B.V.) - evolocumab - EMEA/H/C/003766

Amgen Europe B.V.; Hypercholesterolaemia and mixed dyslipidaemia and Homozygous familial hypercholesterolaemia
Scope: Opinion
Action: For adoption
New active substance (Article 8(3) of Directive No 2001/83/EC)
Oral explanation held on 23.04.2015. List of Outstanding Issues adopted on 23.04.2015. List of Questions adopted on 22.01.2015.
The Committee confirmed that all issues previously identified in this application had been addressed.
The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.
Furthermore, the CHMP considered that evolocumab is a new active substance, as claimed by the applicant.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The legal status was agreed as medicinal product subject to medical prescription.
The summary of opinion was circulated for information.
The Committee adopted the BWP Report.

3.1.10. - asfotase alfa - Orphan - EMEA/H/C/003794

See 3.2.9 and 2.1.4.

3.1.11. Unituxin - dinutuximab – Orphan - EMEA/H/C/002800

United Therapeutics Europe Ltd; treatment of neuroblastoma, treatment of high-risk neuroblastoma
Scope: Opinion
Action: For adoption
New active substance (Article 8(3) of Directive No 2001/83/EC)
List of Outstanding Issues adopted on 22.01.2015. List of Questions adopted on 25.04.2014
The Committee discussed the post authorisation measures and confirmed that all issues previously identified in this application had been addressed.
The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.
Furthermore, the CHMP considered that dinutuximab is a new active substance, as claimed by the applicant.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The legal status was agreed as medicinal product subject to restricted medical prescription.
The summary of opinion was circulated for information.
The Committee adopted the BWP Report.

3.1.12. Nivolumab BMS - nivolumab - EMEA/H/C/003840

Bristol-Myers Squibb Pharma EEIG; treatment of cancer after prior chemotherapy

Scope: Opinion
Action: For adoption
New active substance (Article 8(3) of Directive No 2001/83/EC)
List of Questions adopted on 22.01.2015.
The Committee confirmed that all issues previously identified in this application had been addressed.
The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.
Furthermore, the CHMP considered that nivolumab is a new active substance, as claimed by the applicant.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The legal status was agreed as medicinal product subject to medical prescription.
The Committee noted the letter of recommendation dated 19.05.2015.
The summary of opinion was circulated for information.
The Committee adopted the BWP Report.

3.1.13. Pregabalin Sandoz GmbH - pregabalin - EMEA/H/C/004070

SANDOZ GmbH, treatment of epilepsy and generalised anxiety disorder (GAD) Generic of Lyrica, Duplicate of Pregabalin Sandoz,
Scope: revised Opinion
Action: For adoption
Generic application (Article 10(1) of Directive No 2001/83/EC)
The CHMP adopted the revised opinion after changes to the Product information to bring it in line with other pregabalin PIs via written procedure on 26 May 2015.

3.1.14. Pregabalin Mylan - pregabalin - EMEA/H/C/004078

Generics (UK) Limited, treatment of epilepsy and generalised anxiety disorder (GAD) Generic of Lyrica, Duplicate of Pregabalin Mylan Pharma
Scope: revised Opinion
Action: For adoption
Generic application (Article 10(1) of Directive No 2001/83/EC)
The CHMP adopted the revised opinion after changes to the Product information to bring it in line with other pregabalin PIs via written procedure on 26 May 2015.

3.2. Initial applications; Day 180 list of outstanding issues

3.2.1. - isavuconazole - Orphan - EMEA/H/C/002734

Basilea Medical Ltd; treatment of aspergillosis and mucormycosis
Scope: Day 180 list of outstanding issue
Action: For adoption
List of Questions adopted on 18.12.2014.
The Committee was reminded of the status of this application and its remaining outstanding issues. The Committee considered the need to involve SAG, but concluded that SAG may be necessary at the later stage.

The CHMP adopted a list of Outstanding Issues with a specific timetable.

3.2.2. - p. falciparum circumsporozoite protein fused with hepatitis b surface antigen (rts), and combined with hepatitis b surface antigen (s) in the form of non-infectious virus-like particles (vlps) produced in yeast cells (saccharomyces cerevisiae) by recombinant dna technology - EMEA/H/W/002300

Indicated for active immunisation against malaria
Scope: Day 180 list of outstanding issue
Action: For adoption
List of Questions adopted on 20.11.2014.
The Committee was reminded of the status of this application and its remaining outstanding issues.
The CHMP agreed to consult the SAG Vaccines and adopted a List of Questions to this expert group.
The CHMP adopted a list of Outstanding Issues with a specific timetable.
The Committee adopted the BWP Report.

3.2.3. - nivolumab - EMEA/H/C/003840

See 3.1.12.

3.2.4. - pregabalin - EMEA/H/C/004024

Treatment of neuropathic pain, epilepsy and generalised anxiety disorder (GAD),
Scope: Day 180 list of outstanding issue
Action: For adoption
List of Questions adopted on 18.12.2014.
The Committee was reminded of the status of this application and its remaining outstanding issues.
The CHMP adopted a list of Outstanding Issues with a specific timetable.

3.2.5. - recombinant l-asparaginase - Orphan - EMEA/H/C/002661

medac Gesellschaft fuer klinische Spezialpraeparate mbH; combination therapy for B/T cell lymphoblastic leukaemia (ALL) or B/T cell lymphoblastic lymphoma (LBL)
Scope: Day 180 list of outstanding issue
Action: For adoption
List of Questions adopted on 25.04.2014.
The Committee was reminded of the status of this application and its remaining outstanding issues.
The CHMP adopted a list of Outstanding Issues with a specific timetable.
The Committee adopted the BWP Report.

3.2.6. - pitolisant - Orphan - EMEA/H/C/002616

BIOPROJET PHARMA; treatment of narcolepsy

Scope: Day 180 list of outstanding issue
Action: For adoption
List of Questions adopted on 25.09.2014.
The Committee was reminded of the status of this application and its remaining outstanding issues.
The CHMP adopted a list of Outstanding Issues.
The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the LoOI with a specific timetable.

3.2.7. - sufentanil - EMEA/H/C/002784

Indicated for the management pain
Scope: Day 180 list of outstanding issue
Action: For adoption
List of Questions adopted on 20.11.2014.
The Committee was reminded of the status of this application and its remaining outstanding issues.
The CHMP adopted a list of Outstanding Issues with a specific timetable.

3.2.8. - ceftolozane / tazobactam - EMEA/H/C/003772

Treatment of intra-abdominal urinary tract infections
Scope: Day 180 list of outstanding issue
Action: For adoption
List of Questions adopted on 18.12.2014.
The Committee was reminded of the status of this application and its remaining outstanding issues.
The CHMP adopted a list of Outstanding Issues with a specific timetable.
The CHMP agreed to consult the IDWP and adopted a list of questions to this expert group.

3.2.9. - asfotase alfa - Orphan - EMEA/H/C/003794

Alexion Europe SAS; treatment of paediatric-onset hypophosphatasia
Scope: Day 180 list of outstanding issue
Action: For adoption
List of Outstanding Issues adopted on 26.03.2015. List of Questions adopted on 20.11.2014.
The Committee noted the status of this application and its remaining outstanding issues.
After discussion, the CHMP agreed that no oral explanation was needed at this time.
The CHMP adopted a 2nd list of Outstanding Issues with a specific timetable.
The Committee adopted the BWP Report.

3.2.10. - human heterologous liver cells - Orphan - ATMP - EMEA/H/C/003750

Cytonet GmbH&Co KG; treatment of urea cycle disorders (UCD)
Scope: Day 180 list of outstanding issue
Action: For adoption

List of Outstanding Issues adopted on 18.12.2014. List of Questions adopted on 25.04.2014.
The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee noted the negative draft opinion by consensus adopted by the CAT at their May 2015 Plenary.
The CHMP adopted a list of Outstanding Issues with a specific timetable.
Oral explanation at June 2015 CHMP Plenary.

3.2.11. - idebenone – Orphan - EMEA/H/C/003834

Santhera Pharmaceuticals (Deutschland) GmbH; treatment of Leber's Hereditary Optic Neuropathy (LHON)
Scope: Day 180 list of outstanding issue
Action: For adoption
List of Outstanding Issues adopted on 26.02.2015. List of Questions adopted on 25.09.2014.
The CHMP adopted a list of Outstanding Issues with a specific timetable.
See also 2.1.3

3.2.12. - docetaxel - EMEA/H/C/003925

Treatment of breast cancer, non small cell lung cancer, prostate cancer, metastatic gastric adenocarcinoma and head and neck cancer,
Scope: Day 180 list of outstanding issue
Action: For adoption
List of Outstanding Issues adopted on 26.03.2015. List of Questions adopted on 23.10.2014
The Committee was reminded of the status of this application and its remaining outstanding issues.
The CHMP discussed a 2nd list of Outstanding Issues with a specific timetable.

3.2.13. - aripiprazole - EMEA/H/C/004008

Treatment of schizophrenia and treatment and prevention of manic episodes in bipolar I disorder

Scope: Day 180 list of outstanding issue

Action: For adoption

List of Outstanding Issues adopted on 26.03.2015. List of Questions adopted on 20.11.2014

Discussion in June 2015 CHMP.

3.3. Initial applications; Day 120 list of questions

3.3.1. - atazanavir - EMEA/H/C/004048

Treatment of HIV-1,
Scope: Day 120 list of questions
Action: For adoption
The Committee noted the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the List of Questions.

3.3.2. - cinacalcet - EMEA/H/C/004014

Treatment of secondary hyperparathyroidism and hypercalcaemia,
Scope: Day 120 list of questions
Action: For adoption
The Committee noted the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the List of Questions.

3.3.3. - sacubitril / valsartan - EMEA/H/C/004062

Treatment of heart failure (NYHA class II-IV)
Scope: Day 120 list of questions
Action: For adoption
The Committee noted the issues identified in this application,
The CHMP agreed to consult Healthcare Professional's Working Party (HCPWP) and adopted a list of questions to this group.

The Committee adopted the CHMP recommendation and scientific discussion together with the List of Questions.

3.3.4. - lopinavir / ritonavir - EMEA/H/C/004025

Treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children above the age of 2 years,
Scope: Day 120 list of questions
Action: For adoption
The Committee noted the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the List of Questions .

3.3.5. - diphtheria, tetanus, pertussis (acellular, component), hepatitis b (rdna), poliomyelitis (inact.) and haemophilus type b conjugate vaccine (adsorbed) - EMEA/H/C/003982

Vaccination against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae typeb (Hib)

Scope: Day 120 list of questions
Action: For adoption
The Committee noted the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the List of Questions.

3.3.6. - lesinurad - EMEA/H/C/003932

Treatment of hyperuricaemia
Scope: Day 120 list of questions
Action: For adoption
The Committee noted the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the List of Questions.

3.4. Update on on-going initial applications for Centralised procedure

3.4.1. ferric citrate coordination complex - EMEA/H/C/003776

Treatment of hyperphosphataemia
Scope: Request for revision of legal status
Action: For discussion
List of Outstanding Issues adopted on 26.03.2015. List of Questions adopted on 24.07.2014.

3.4.2. - glycopyrronium bromide - EMEA/H/C/003883

Treatment of sialorrhoea
Scope: Legal basis
Action: For discussion
The CHMP noted the update on the regulatory aspects of the procedure.

3.4.3. - methotrexate - EMEA/H/C/003756

Treatment of rheumatological and dermatological diseases
Scope: Similarity assessment report
Action: For adoption
The CHMP adopted the CHMP Similarity Assessment Report .

3.4.4. - guanfacine - EMEA/H/C/003759

Treatment of ADHD
List of Outstanding Issues adopted on 26.03.2015. List of Questions adopted on 24.07.2014.
The CHMP adopted the list of experts for the SAG Psychiatry meeting to be held on 1 June 2015.

3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004

No items

3.6. Initial applications in the decision-making phase

No items

3.7. Withdrawals of initial marketing authorisation application

3.7.1. Aripiprazole Mylan - Aripiprazole - EMEA/H/C/003926

GENERICS (UK) LIMITED;
Rapporteur: Milena Stain,
Scope: Withdrawal
Action: For information
Generic application (Article 10(1) of Directive No 2001/83/EC)
The CHMP noted the letter from the applicant dated 7 May 2015 informing of the decision to withdraw the MAA.

4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion

4.1.1. Somavert - pegvisomant - EMEA/H/C/000409/X/0072

Pfizer Limited;
Rapporteur: Joseph Emmerich, PRAC Rapporteur: Arnaud Batz;
Scope: "Addition of 25 mg and 30 mg powder and solvent for solution for injection."
Action: For adoption
List of Outstanding Issues adopted on 26.02.2015. List of Questions adopted on 25.09.2014.
The Committee confirmed that all issues previously identified in this application had been resolved.
The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.
The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.
The summary of opinion was circulated for information.
The CHMP adopted the CHMP Similarity Assessment Report .

4.1.2. Zostavax - shingles (herpes zoster) vaccine (live) - EMEA/H/C/000674/X/0085

See 4.3.1.

4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues

4.2.1. Kalydeco - ivacaftor - Orphan - EMEA/H/C/002494/X/0034/G

Vertex Pharmaceuticals (U.K.) Ltd.;
Rapporteur: Concepcion Prieto Yerro, Co-rapporteur: Melinda Sobor, PRAC Rapporteur: Miguel-Angel Macia;
Scope: "Line extension to the Marketing Authorisation to include a new pharmaceutical form (granules) in two new strengths (50 mg and 75 mg unit doses) to enable administration of Kalydeco to patients aged 2 to less than 6 years of age. Changes to SmPC sections 4.2, 4.4, 4.5, 4.8 and 5.2 to provide clarity and relevant updates in line with the proposed paediatric extension application. Consequential changes are made to the Package Leaflet."
Action: For adoption
List of Questions adopted on 26.02.2015.
The Committee was reminded of the status of this application and its remaining outstanding issues.
The CHMP adopted a 2nd list of Outstanding Issues with a specific timetable.

4.2.2. Suboxone - buprenorphine / naloxone - EMEA/H/C/000697/X/0029

RB Pharmaceuticals Ltd.;
Rapporteur: Martina Weise;
Scope: "Line extension application to add 12mg/3mg and 16mg/4mg sublingual tablets."
Action: For adoption
List of Questions adopted on 22.01.2015.
The Committee was reminded of the status of this application and its remaining outstanding issues. The members discussed the available bioequivalence data for the two concentrations 12/3 mg and 16/4 mg SL tablets. Higher plasma concentrations for the 12/3 mg formulation were noted which raised questions on the acceptability of the bioequivalence.
The CHMP adopted a 2nd list of Outstanding Issues with a specific timetable.

4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question

4.3.1. Zostavax - shingles (herpes zoster) vaccine (live) - EMEA/H/C/000674/X/0085

Sanofi Pasteur MSD SNC;
Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski;
Scope: "Addition of the route of administration "intramuscular" for all presentations."
Action: For adoption
The Committee discussed the issues identified in this application which related to the SmPC wording as well as the IMP batches used in the clinical study.
The CHMP adopted a List of Questions with a specific timetable.

4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008

No items

4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

No items

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information

5.1.1. Cimzia - certolizumab pegol - EMEA/H/C/001037/II/0045

UCB Pharma SA;
Rapporteur: Kristina Dunder, Co-rapporteur: Agnes Gyurasics;
Scope: "Extension of indication to include treatment of severe, active and progressive rheumatoid arthritis in adults not treated previously with MTX or other disease-modifying antirheumatic drugs (DMARDs).
As a consequence, sections 4.1, 4.8 and 5.1 of the SmPC are revised in order to update the efficacy and safety information."
Action: For adoption
The Committee discussed the issues identified in this application, which related to the wording of different parts of the SmPC and some efficacy aspects.
The Committee adopted a Request for Supplementary Information with a specific timetable.

5.1.2. CYRAMZA - ramucirumab - Orphan - EMEA/H/C/002829/II/0003

Eli Lilly Nederland B.V.;
Rapporteur: Pieter de Graeff, Co-rapporteur: Kolbeinn Gudmundsson, PRAC Rapporteur: Brigitte Keller-Stanislawski;
Scope: "Extension of Indication to include new indication for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with progression after platinum-based chemotherapy for CYRAMZA.
As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance.
In addition, one minor typographical error was corrected in section 4.2 of the SmPC."
Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)
Action: For adoption

The Committee discussed the issues identified in this application, mainly relating to the benefit/risk of the product in the proposed indication, as well as the significant clinical benefit in comparison with existing therapies in relation to the request for 1 year market protection.
The Committee adopted a Request for Supplementary Information with a specific timetable.

5.1.3. Fycompa - perampanel - EMEA/H/C/002434/II/0016

Eisai Europe Ltd.;
Rapporteur: Robert James Hemmings, Co-rapporteur: Pierre Demolis, PRAC Rapporteur: Julie Williams;
Scope: "Extension of indication to include a new indication for Fycompa for adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy. Consequently, the MAH proposed an update of sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC. Particularly, a new warning with regard to the lack of a demonstrated effect on other generalised seizure types has been added to the product information. In addition, minor editorial changes and amendments to improve the clarity and readability of the information were implemented throughout the product information. The Package Leaflet was proposed to be updated accordingly. In addition, the MAH took the opportunity to updates the contact details of the local representatives of Belgium, Luxembourg and Malta."

Action: For adoption
Request for Supplementary Information adopted on 26.03.2015 and 18.12.2014.
The members discussed the best section in the SmPC to include information on the lack of evidence for efficacy and safety data for other types of generalized seizures (i.e. myoclonic seizures and absence seizures). Views in favour of sections 4.4 and 5.1 were expressed. The Committee agreed to include the data in section 5.1 with a reference in section 4.1 following the advice from the EMA.
The Committee confirmed that all issues previously identified in this application had been resolved.
The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.
The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.
The summary of opinion was circulated for information.

5.1.4. Imbruvica - ibrutinib - Orphan - EMEA/H/C/003791/II/0001

Janssen-Cilag International NV;
Rapporteur: Filip Josephson, Co-rapporteur: Christian Schneider, PRAC Rapporteur: Julie Williams;
Scope: "Extension of Indication to add treatment of adult patients with Waldenström's macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC and the Package Leaflet have been updated accordingly. In addition, the MAH took the opportunity to implement minor editorial changes in the SmPC. Furthermore, an updated RMP version 4.0 was approved as part of the application."

Action: For adoption
Request for Supplementary Information adopted on 26.02.2015.
The Committee discussed the wording of the indication and confirmed that all issues previously identified in this application had been resolved.
The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.
The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.
The summary of opinion was circulated for information.

5.1.5. Kuvan – sapropterin – EMEA/H/C/000943/II/0033 - Orphan

Merck Serono Europe Limited
Rapporteur: Patrick Salmon, Co-Rapporteur: Daniel Brasseur,
Scope: "Extension of indication for the 'treatment of hyperphenylalaninaemia (HPA) in adults and paediatric patients of 4 years of age and over with phenylketonuria (PKU) who have shown to be responsive to such treatment' to include the paediatric population under 4 years old. Sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC and the Package Leaflet are updated accordingly."
Request for Supplementary Information adopted on 23.04.2015, 26.02.2015.
Action: For adoption
The Committee confirmed that all issues previously identified in this application had been resolved.
The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.
The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.
The summary of opinion was circulated for information.

5.1.6. Perjeta - pertuzumab - EMEA/H/C/002547/II/0010

Roche Registration Ltd;
Rapporteur: Christian Schneider, Co-rapporteur: Daniela Melchiorri, PRAC Rapporteur: Doris Stenver;
Scope: "The MAH is submitting a type II 90 day variation application to extend the use of Perjeta in combination with trastuzumab and docetaxel as part of a neoadjuvant treatment for patients with locally advanced, inflammatory or early stage HER2-positive breast cancer suitable for neoadjuvant therapy (tumors > 2 cm in diameter).
The submission is based primarily on the results of two randomized Phase II studies, NEOSPHERE (WO20697) and TRYPHAENA (BO22280).
The Perjeta annexes have been updated in the concerned sections as outlined in the table below and in the SmPC track change version in Module 1.3.1.
The section 4.8 Undesirable effects of the SmPC (and the section 4 of the PIL accordingly) has been revised and includes now a pooled safety analysis across the studies CLEOPATRA, the pivotal study in metastatic breast cancer, and the two neoadjuvant studies NEOSPHERE and TRYPHAENA. A "Note to the Reviewer" providing further explanations on the pooled safety analysis is also included in the track change SmPC version in Module 1.3.1."
Action: For adoption

See also 2.3.1
Request for Supplementary Information adopted on 18.12.2014.
The Committee noted the SAG Oncology conclusion that, taking into consideration the totality of data, it is reasonably likely that neoadjuvant treatment with pertuzumab is associated with a benefit in terms of disease-free survival (DFS) and overall survival (OS).
Oral explanation was held on Tuesday 19 May 2015 at time 09:00. During the oral explanation, company presented the answers to the CHMP list of questions, which were about the use of pertuzumab in the neoadjuvant setting in patients with HR+/HER2+ tumours, the B/R of pertuzumab in the neoadjuvant setting in patients with primarily operable breast cancer. The company also discussed the mechanism of action of pertuzumab, the safety profile of pertuzumab, and current standard of care as part of their responses.The Committee discussed the NEOSPHERE and TRYPHAENA study results and design. The Committee noted that there are uncertainties with regard to the long-term benefit and long-term safety. Some members expressed their view that the results of the APHINITY study should be awaited before granting a MA in patients with HR+ tumours. The uncertainties could be considered overcome by restricting the indication to inoperable disease, since this represents a high-risk setting.
The Committee adopted a Request for Supplementary Information with a specific timetable.

5.1.7. Simponi - golimumab - EMEA/H/C/000992/II/0061

Janssen Biologics B.V.;
Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga;
Scope: “Extension of Indication to include a new indication for the treatment of non radiographic axial spondyloarthritis (nr Axial SpA) for Simponi (Golimumab). As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC have been updated. The Package Leaflet is updated in accordance.
In addition, the MAH took the opportunity to correct some minor editorial mistakes in the Product Information.”
Action: For adoption
Request for Supplementary Information adopted on 26.02.2015.
The Committee confirmed that all issues previously identified in this application had been resolved.
The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.
The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.
The summary of opinion was circulated for information.

5.1.8. Stelara - ustekinumab - EMEA/H/C/000958/II/0042

Janssen-Cilag International N.V.;
Rapporteur: Greg Markey, Co-rapporteur: David Lyons, PRAC Rapporteur: Julie Williams;
Scope: “Extension of Indication to add treatment of moderate to severe plaque psoriasis in paediatric patients from the age of 12 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies. As a consequence SmPC sections 4.1, 4.2, 4.8, 5.1, 5.2 and 6.6 have been updated and the Package Leaflet has been updated accordingly. A revised RMP version 12 was provided as part of the application.”

Action: For adoption
Request for Supplementary Information adopted on 22.01.2015.
The Committee confirmed that all issues previously identified in this application had been resolved.
The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.
The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.
The Committee noted the letter of recommendation dated 13.05.2015.
The summary of opinion was circulated for information.

5.1.9. TachoSil - human thrombin / human fibrinogen - EMEA/H/C/000505/II/0057

Takeda Austria GmbH;
Rapporteur: Jan Mueller-Berghaus, Co-rapporteur: Greg Markey, PRAC Rapporteur: Brigitte Keller-Stanislawski;
Scope: "Extension of indication for the use of Tachosil as suture line sealing in dura mater closure. As a consequence, sections 4.1, 4.2, 4.4, 4.8, and 5.1 of the SmPC and the Package leaflet are updated. The MAH also took the opportunity to make minor editorial corrections to the product information."
Action: For adoption
Request for Supplementary Information adopted on 22.01.2015.
The Committee discussed the issues identified in this application, mainly relating to the clinical trial results.
The Committee adopted a Request for Supplementary Information with a specific timetable.

5.1.10. Voncento - human coagulation factor viii / human von willebrand factor - EMEA/H/C/002493/II/0008/G

CSL Behring GmbH;
Rapporteur: Pieter de Graeff, Co-rapporteur: Greg Markey, PRAC Rapporteur: Sabine Straus;
Scope: "Extension of indication to include prophylactic treatment of patients with VWD. In addition the MAH is providing data to support treatment of paediatric patients with VWD."
Action: For adoption
Request for Supplementary Information adopted on 18.12.2014.
The Committee discussed the issues identified in this application, mainly relating to the posology in children. Furthermore adverse drug reactions in the elderly were discussed.
The Committee adopted a Request for Supplementary Information with a specific timetable.

5.1.11. Xultophy - insulin degludec / liraglutide - EMEA/H/C/002647/II/0002

Novo Nordisk A/S;
Rapporteur: Kristina Dunder, Co-rapporteur: Robert James Hemmings, PRAC Rapporteur: Menno van der Elst;
Scope: "Extension of indication for Xultophy to include transfer of patients from Glucagon-Like peptide-1 (GLP1) receptor agonist (RA) treatment to Xultophy. Consequently, the MAH

proposed the update of sections 4.1, 4.2, 4.4, and 5.1 of the SmPC. The Package Leaflet is updated accordingly."

Action: For adoption

Request for Supplementary Information adopted on 26.03.2015.

The Committee confirmed that all issues previously identified in this application had been resolved.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

5.3. Re-examination of Type II variation; extension of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

6. Ancillary medicinal substances in medical devices

6.1. Ancillary medicinal substances in medical devices; Opinions/ Day 180 list of outstanding issues / Day 120 list of questions

No items

7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use

7.1.1. Daclastavir – Daclastavir – EMEA/H/K/0003867/OTH/0001H000

Scope: Annual Safety Report as per Article 83 of Regulation (EC) No 726/2004 commitment (compassionate use daclatasvir CHMP Opinion 21 Nov 2013), covering period from 16 November 2013 to 15 November 2014

Action: For adoption

The CHMP adopted the annual safety report.

8. Pre-submission issues

8.1. Pre-submission issue

8.1.1. H0004124

Treatment for patients with progressing advanced/metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) who have received prior EGFR TKI therapy
Scope: Request for an accelerated review
Action: For adoption
Rapporteurs' accelerated assessment briefing note
The CHMP agreed to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the request for accelerated assessment.
H0004059 - OrphanAmicus Therapeutics UK Ltd ; indicated for long-term treatment of adult (18 to 74 years) and adolescent (16 to 18 years) patients with a confirmed diagnosis of Fabry disease (α-galactosidase-A deficiency) and who have an amenable genotype base as defined in: Amicus@look-uptable.com
Scope: Request for an accelerated review
Action: For adoption
Rapporteurs' accelerated assessment briefing note
The CHMP agreed to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the request for accelerated assessment.

9. Post-authorisation issues

9.1. Post-authorisation issues

9.1.1. Onglyza - Saxagliptin, Saxagliptin Hydrochloride - EMEA/H/C/001039/LEG 038

AstraZeneca AB
Rapporteur: Pieter de Graeff, Co-Rapporteur: Karsten Bruins Slot,
(treatment of type 2 diabetes mellitus), New active substance (Article 8(3) of Directive No 2001/83/EC)
Scope: In 2014, the CHMP assessed a Type II variation (WS/0529/G) to reflect data outcomes from the SAVOR study in the product information. In April 2015, new FDA analyses relating to the SAVOR study were made available. Based on the new data and the assessment of the MAH's responses to a CHMP list of questions adopted in April 2015, the CHMP requested advice from the PRAC. Based on the review of the available information, the PRAC agreed that further clarification was needed regarding the underlying reasons for the observed imbalance in all-cause mortality before any conclusions on causality can be drawn. The PRAC agreed a list of questions to be addressed to the MAH. The PRAC will provide CHMP with further advice in September 2015 following the assessment of the MAH's responses to the list of questions.
Action: For adoption
See also 9.1.2
The Committee discussed the issues identified in this application.
The Committee adopted a Request for Supplementary Information with a specific timetable.

9.1.2. Komboglyze - Metformin Hydrochloride, Saxagliptin Hydrochloride - EMEA/H/C/002059/LEG 015

AstraZeneca AB
Rapporteur: Pieter de Graeff, Co-Rapporteur: Karsten Bruins Slot,
Scope: In 2014, the CHMP assessed a Type II variation (WS/0529/G) to reflect data outcomes from the SAVOR study in the product information. In April 2015, new FDA analyses relating to the SAVOR study were made available. Based on the new data and the assessment of the MAH's responses to a CHMP list of questions adopted in April 2015, the CHMP requested advice from the PRAC. Based on the review of the available information, the PRAC agreed that further clarification was needed regarding the underlying reasons for the observed imbalance in all-cause mortality before any conclusions on causality can be drawn. The PRAC agreed a list of questions to be addressed to the MAH. The PRAC will provide CHMP with further advice in September 2015 following the assessment of the MAH's responses to the list of questions.
Action: For adoption
See also 9.1.1
The Committee discussed the issues identified in this application.
The Committee adopted a Request for Supplementary Information with a specific timetable.

9.1.3. BeneFIX - nonacog alfa - EMEA/H/C/000139/II/0131

Pfizer Limited
Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski,
Scope: Opinion or Request for supplementary information
Update of sections 4.2, 5.1, and 5.2 of the SmPC in order to update the posology with once-weekly prophylaxis regimen. The RMP is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to introduce minor editorial changes to the PI.
Action: For adoption
The Committee discussed the issues identified in this application, mainly relating to the clinical efficacy and the pharmacokinetics.
The Committee adopted a Request for Supplementary Information with a specific timetable.

9.1.4. Labelling for medicinal products for type 2 diabetes

Rapporteur: Kristina Dunder
Scope: Response letter
Action: For discussion
Letter regarding approved labelling for medicinal products for type 2 diabetes.

9.1.5. Replagal - agalsidase alfa - EMEA/H/C/000369/S/0086

Shire Human Genetic Therapies AB
Rapporteur: Pieter de Graeff, PRAC Rapporteur: Sabine Straus,
Scope: Opinion or Request for supplementary information

13th Annual Reassessment.
Action: For adoption
Request for Supplementary Information adopted on 26.02.2015.
The Committee confirmed that all issues previously identified in this application ad been addressed.
The Committee adopted a positive opinion by consensus together with the CHMP Assessment report and Translation timetable recommending switching to full marketing authorisation.
The Icelandic and Norwegian members were in agreement with the CHMP recommendation.

9.1.6. Remicade - infliximab - EMEA/H/C/000240/II/0188

Janssen Biologics B.V.
Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga,
Scope: Opinion or Request for supplementary information, LoQ to the VWP
Update of sections 4.4, 4.5, 4.6 and 4.8 of the SmPC in order to include updated pregnancy information following submission of the final report of the Pregnancy and Infant Outcomes Registry and additional reports on infections and agranulocytosis in neonates and infants in utero exposure to Remicade. The Package Leaflet is updated accordingly. Furthermore, the Patient Alert Card which is part of Annex III A is updated accordingly.
In addition, the Marketing authorisation holder took the opportunity to revise Annex II D to bring it in line with Annex 10 of the RMP. The updated RMP version 11.0 has been submitted
Action: For adoption

The Committee discussed the issues identified in this application,

The Committee adopted a Request for Supplementary Information with a specific timetable.

The Committee adopted the list of questions to the VWP.

9.1.7. TECFIDERA - Dimethyl Fumarate - EMEA/H/C/002601/WS0689/G; NAPs included in WS: Fumaderm, Fumaderm Intial

MAH: Biogen Idec Ltd, treatment of multiple sclerosis
Rapporteur: Martina Weise, Co-Rapporteur: Robert James Hemmings,
Scope: List of experts to SAG Neurology
Action: For adoption
The CHMP adopted the list of experts to the SAG Neurology.

9.1.8. Ferriprox - deferiprone - EMEA/H/C/000236/II/0089/G

Apotex Europe BV,
Rapporteur: Pierre Demolis, PRAC Rapporteur: Arnaud Batz,
Scope: Request for an extension of timeframe for submission of responses to the Request for supplementary information adopted in February 2015.
Update of section 4.5 of the SmPC regarding combination of deferiprone with other iron chelators further to request of the PRAC in the assessment of the PSUR (PSUV/083). Update of section 5.1 of the SmPC and the RMP with the results of Study LA37-111 conducted to evaluate the effect of deferiprone on cardiac QT and QTC interval duration. The Package leaflet is updated accordingly. The MAH also takes the opportunity to align the product

information with QRD template (version 9) and to make minor editorial corrections. The package leaflet is also updated to add the local representatives in Croatia.
Action: For adoption
Request for Supplementary Information adopted on 26.02.2015, 20.11.2014, 24.07.2014.
Oral explanation held on 26.02.2015.
The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the 3rd Request for Supplementary Information adopted on 26.02.2015.

9.1.9. Mysimba - Bupropion Hydrochloride, Naltrexone Hydrochloride - EMEA/H/C/003687

Orexigen Therapeutics Ireland Limited, indicated for the management of obesity
Rapporteur: Jens Heisterberg, Co-Rapporteur: Robert James Hemmings,
Fixed combination application (Article 10b of Directive No 2001/83/EC)
Action: For information/ discussion
The CHMP noted the publication of the interim analysis of 50% of the expected data. The members agreed that no immediate actions were required but to wait for the assessment of the data which will be received in June 2015.

9.1.10. Tygacil - tigecycline - EMEA/H/C/000644

Pfizer Limited
Rapporteur: Arantxa Sancho-Loez, Co-Rapporteur: Outi Maki-Ikola,
Action: For information/ discussion
The NCAs will be informed by EMA.
List of questions adopted.

10. Referral procedures

10.1. Procedure for Centrally Authorised products under Article 20 Council Regulation (EC) No 726/2004

10.1.1. Tysabri - Natalizumab - EMEA/H/C/000603

Biogen Idec Ltd; treatment of multiple sclerosis
Rapporteur: Jan Mueller-Berghaus, Co-rapporteur: Daniela Melchiorri, PRAC Rapporteur: Brigitte Keller-Stanislawski;
Scope: Review of the benefit-risk balance following notification by the European Commission of a referral under Article 20 of Regulation (EC) No 726/2004, based on pharmacovigilance data (natalizumab has been associated with an increased risk of progressive multifocal leukoencephalopathy, risk factors are known).
Action: For information
Procedure was started at PRAC. The CHMP noted the letter from the European Commission received 29 April 2015 informing of an official referral under Article 20 and its grounds.

10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004

No items

10.3. Procedure under Articles 5(2) and 10 of the Regulation (EC) No 726/2004

No items

10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC

No items

10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC

No items

10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC

No items

10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC

10.7.1. GVK Biosciences - - (EMEA/H/A-31/1408)

Re-examination Rapporteur: Hubert Leufkens, Re-examination Co-rapporteur: Karsten Bruins Slot
Scope: Re-examination Opinion
Article 31 procedure triggered by the European Commission concerning GVK Biosciences Private Limited (GVK Bio), Swarna Jayanthi commercial complex, Ameerpet, Hyderabad 500 038, India following critical GCP deficiencies reported during an inspection performed by the ANSM (Agency for Medicines and Health Products Safety, France) on 19-23 May 2014.
Action: For adoption
See also 2.2.1.
Opinion adopted on 22.01.2015. The re-examination procedure started on 31 March 2015.

Based on the totality of the data available, including the information submitted during the original assessment procedure and the detailed grounds for re-examination put forward by the MAHs, the Committee adopted the following opinion by consensus:

- The Committee concluded that the benefit risk of Nebivolol/Neo Balkanika is positive, therefore Nebivolol/Neo Balkanika is included in the list of medicinal products recommended for maintenance of the marketing authorisation;

- The Committee confirmed its previous recommendation to suspend the marketing authorisations for medicinal products for which bioequivalence vis-à-vis the EU reference

medicinal product was not established. The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The Committee agreed to the EMA public health communication.

10.8. Procedure under Article 107(2) of Directive 2001/83/EC

No items

10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) (EC) No 1084/2003

No items

10.10. Procedure under Article 29 Regulation (EC) 1901/2006

No items

10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) No 1234/2008)

No items

11. Pharmacovigilance issue

11.1. Early Notification System

May 2015 Early Notification System on Envisaged CHMP Recommendations for Regulatory Action (based on Identified Safety Concerns) Accompanied by Communication to the General Summary of recommendations and advice of PRAC meeting held on 4-7May 2015.

Action: For information

11.1.1. Gilenya - Fingolimod Hydrochloride - EMEA/H/C/002202

Novartis Europharm Ltd, treatment of multiple sclerosis
Rapporteur: Pierre Demolis, Co-Rapporteur: Filip Josephson,
Scope: PRAC List of Questions for a multidisciplinary SAG/ad hoc expert advisory group for fingolimod regarding the risk factors for progressive multifocal leukoencephalopathy (PML) and the monitoring of patients treated with fingolimod.
Action: For adoption
The CHMP adopted the List of Questions to the SAG/ad-hoc expert group.

12. Inspections

12.1. GMP inspections

Disclosure of information related to GMP inspections will not be published as it undermines the purpose of such inspections

12.2. GCP inspections

Disclosure of information related to GCP inspections will not be published as it undermines the purpose of such inspections

12.3. Pharmacovigilance inspections

Disclosure of information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections

12.4. GLP inspections

Disclosure of information related to GLP inspections will not be published as it undermines the purpose of such inspections

13. Innovation Task Force

13.1. Minutes of Innovation Task Force

Action: For information

13.2. Innovation Task Force briefing meetings

Disclosure of information related to briefing meetings taking place with applicants cannot be released at present time as deemed to contain commercially confidential information

13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004

13.4. Nanomedicines activities

14. Organisational, regulatory and methodological matters

14.1. Mandate and organisation of the CHMP

No items

14.2. Coordination with EMA Scientific Committees

14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC)

Summary of recommendations and advice of PRAC meeting held on 4-7 May 2015

Action: For information

The Committee noted the report.

The members noted the Summary of recommendations and advices of the PRAC meeting.

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for May 2015

Action: For adoption

The EURD list was adopted.

14.2.2. Committee for Advanced Therapies (CAT)

CAT draft minutes of meeting held on 12-13 May 2015

Action: For information

The CHMP noted the draft Minutes.

14.2.3. Committee for Herbal Medicinal Products (HMPC)

Report from the HMPC meeting held on 4-7 May 2015

Action: For information

The CHMP noted the report.

14.2.4. Paediatric Committee (PDCO)

PIPs reaching D30 at May 2015 PDCO

Action: For information

The CHMP noted the report.

Report from the PDCO meeting held on 20-22 May 2015.

Action: For information

The CHMP noted the report.

14.2.5. Committee for Orphan Medicinal Products (COMP)

Report from the COMP meeting held on 12-13 May 2015

Action: For information

The CHMP noted the report.

14.2.6. CMDh

Report from the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) on the meeting held on 18-20 May 2015

Action: For information

The CHMP noted the report

14.3. Coordination with EMA Working Parties / Working Groups / Drafting Groups

14.3.1. Scientific Advice Working Party (SAWP)

Report from the SAWP meeting held on 4-7 May 2015. Table of conclusions

Action: For information

The CHMP noted the report.

Scientific advice letters:
Disclosure of information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.

First draft of Scientific Guidance on Post-authorisation Efficacy Studies (PAES)

Action: For information

Postponed to June 2015 CHMP

14.3.2. Quality Working Party (QWP)

Reflection paper on the use of Cocrystals of active substances in medicinal products (EMA/CHMP/CVMP/QWP/284008/2015)
Action: For adoption

This reflection paper is intended to reflect the current thinking of the CHMP/CVMP regarding different aspects concerning the use of cocrystals of active substances in medicinal products, for either human or veterinary use. These different aspects are also compared for some other solid state forms and include, for example, the applicability of Article 10(2)(b) of Directive 2001/83/EC and Article 13(2)(b) of Directive 2001/82/EC, the acceptability of the Active Substance Master File (ASMF) procedure and the possibility to include different solid state forms within the same marketing authorisation.
The CHMP adopted the reflection paper.

14.3.3. Cardiovascular Working Party

Paediatric Addendum on the CHMP Guideline on clinical investigation of medicinal products for the treatment of acute heart failure (EMA/CHMP/707532/2013)

Action: For adoption for 6-months public consultation

The guideline includes the design and conduct of studies intended for use in children of all ages (0-18 years) when developing products for acute heart failure. The discussion points include clinical trial designs, selection of patients (in relation to the heterogeneity of the population), primary and secondary end points, a note on surrogate and composite endpoints, and safety endpoints. Safety endpoints differ in children as compared to the adult population.
The CHMP adopted the addendum for 6-months public consultation.

Guideline on clinical investigation of medicinal products for the treatment of acute heart failure (EMA/CHMP/268124/2015)

Action: For adoption

The guideline provides guidance to applicants on the main regulatory requirements that are expected in the development of a medicinal product for treatment of AHF in adults. The main focus of the document will be pharmacological intervention of left ventricular dysfunction with or without concomitant right ventricular dysfunction. Other trials and

interventions, including pacing modalities or other devices to provide mechanical support, are not within the scope of this document.
The CHMP adopted the guideline.

14.3.4. Excipients Drafting Group

Questions and answers on Sodium as an excipient in the context of the revision of the guideline on 'Excipients in the label and package leaflet of medicinal products for human use' (CPMP/463/00 Rev.1) (EMA/CHMP/338679/2014)

Action: For adoption
A questions and answers (Q&A) documents on excipients are progressively released for public consultation. They include proposals for new or updated information for the label and package leaflet.
When one or several Q&As have been finalised, the new information in the package leaflet will be included in a revised annex of the guideline.
The CHMP adopted the questions-and-answers documents.

Questions and Answers on Wheat starch (containing gluten) in the context of the revision of the guideline on 'Excipients in the label and package leaflet of medicinal products for human use' (CPMP/463/00 Rev. 1) (EMA/CHMP/704219/2013)

Action: For adoption
A questions and answers document (Q&A) with a detailed background review are created to support a progressive release of information and provide the scientific rationale for the updated information in the package leaflet.
The CHMP adopted the questions-and-answers documents.

Submission of comments on "Questions and answers on wheat starch (containing gluten) in the context of the revision of the guideline on 'Excipients in the label and package leaflet of medicinal products for human use' (CPMP/463/00 Rev. 1)" - EMA/CHMP/704219/2013 (EMA/CHMP/674221/2014)

Action: For information
The CHMP noted the comments.

Background review for the excipient wheat starch (containing gluten) (EMA/CHMP/639441/2013)

Action: For adoption
The CHMP adopted the background review.

14.3.5. Pharmacokinetics Working Party

Finalised product-specific bioequivalence guidance: last guidance from first batch

Action: For adoption

The aim of publishing product-specific guidance on demonstration of bioequivalence is to enable a consistent approach to the assessment of applications based on bioequivalence data, particularly generic applications, across all submission routes, i.e. submitted centrally, via the decentralised procedure or mutually recognition procedure, or nationally. The last guidance from the first batch covers following active substances: sirolimus, sorafenib, sunitinib, tadalafil, telithromycin, voriconazole, capecitabine.

The CHMP adopted the guidance.

14.3.6. Biostatistics Working Party

Q&A document to supplement the CHMP Data Monitoring Committee Guideline - request to clinical assessors to add additional questions

Action: For discussion

As per the BSWP 2015 work plan, BSWP is considering the possible development of a Q&A document to supplement the CHMP Data Monitoring Committee Guideline (Doc ref. EMEA/CHMP/EWP/5872/03).
In particular there have been questions on the role and necessity for a Data Monitoring Committee (DMC) in different phases of drug development as well as with regard to the responsibilities for implementing DMC decisions. The Q&A document would provide answers to such (and other) questions.
To that end BSWP would like to ask clinical assessors for possible questions and answers related to DMC. This draft list is a starting point and includes Q&A from clinical assessors from the Paul Ehrlich Institut.
The clinical assessors from all other agencies are requested to add further Q&A (if any).
The CHMP noted the request and further discussion is expected on the Q&A document Responses by the clinical assessors should be sent **by 30 June.**

14.3.7. Safety Working Party

Revised SWP Work plan 2015

Action: For adoption

The CHMP adopted the revised SWP Work Plan 2015.

14.3.8. Ad-hoc Influenza Working Group:

EU Strain selection for the Influenza Vaccines for the Season 2015/2016

Updated EU Recommendation for the Seasonal Influenza Vaccine Composition for the Season 2015/2016.

Updated report from Ad Hoc Influenza working group to the BWP

Action: For adoption

The CHMP adopted the updated EU recommendation and report.

14.4. Cooperation within the EU regulatory network

14.4.1. EU Medicines Agencies Network Strategy to 2020: Working Together to Improve Health – consultation phase

The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) have released the 'EU Medicines Agencies Network Strategy to 2020', a draft common strategy to 2020 for the European medicines agencies network (http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000292.jsp&mid=WC0b01ac05800293a4)

Action: For discussion

The CHMP noted the presentation. The draft strategy focuses on areas where collaboration within the network can make a real difference to human and animal health in the EU over the five years to 2020. Committee members are invited to send their comments until 15 June 2015.

14.5. Cooperation with International Regulators

No items

14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee

No items

14.7. CHMP work plan

No items

14.8. Planning and reporting

No items

15. Any other business

15.1. Revision of the Accelerated Assessment guideline

The members noted the proposal for revision of the accelerated assessment guideline, following the Presidency meeting in Uppsala. The revision will be discussed during the Strategic Review and Learning meeting in Ljubljana. The comments are awaited until June 15. Further discussions will continue in June Plenary.

15.2. Assessment timetables for type II variations

Action: For discussion
Minor amendments, which do not affect submission dates, were deemed necessary in the assessment timetables for type II variations involving the PRAC. These will be applicable as of June 2015 and relevant timetables on the Agency's website will be updated accordingly by June 30th.

The CHMP agreed to the revised assessment timetables for type II variations.

15.3. Expertise of CHMP members and alternates

The members noted the current expertise of the CHMP members and alternates. The required expertise for a co-opted member will be further discussed and agreed during the June CHMP Plenary meeting.

15.4. Final Agenda of the strategic review and learning Joint CHMP and CAT Meeting under Latvian EU Presidency, Ljubljana, SLOVENIA May 26-28, 2015

The members noted the final agenda of the Presidency meeting

16. List of participants

List of participants including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 18-21 May 2015 meeting.

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Tomas Salmonson	Chair	Sweden	No interests declared	
Andrea Laslop	Member	Austria	No interests declared	
Milena Stain	Alternate	Austria	No interests declared	
Daniel Brasseur	Member	Belgium	No interests declared	
Bart Van der Schueren	Alternate	Belgium	No interests declared	
Mila Vlaskovska	Member	Bulgaria	No interests declared	
Viola Macolić Šarinić	Member	Croatia	No interests declared	
Ana Dugonjić	Alternate	Croatia	No interests declared	
Panayiotis Triantafyllis	Member	Cyprus	No interests declared	
Ondřej Slanař	Member	Czech Republic	No participation in discussions, final deliberations and voting on:	3.3.2. - cinacalcet - EMEA/H/C/004014
Radka Montoniová	Alternate	Czech Republic	No interests declared	
Jens Heisterberg	Member	Denmark	No restrictions applicable to this meeting	
Christian Schneider	Alternate	Denmark	No interests declared	
Alar Irs	Member	Estonia	No restrictions applicable to this meeting	
Outi Mäki-Ikola	Member	Finland	No restrictions applicable to this meeting	
Pierre Demolis	Member (Vice-Chair)	France	No interests declared	
Joseph Emmerich	Alternate	France	No interests declared	
Harald Enzmann	Member	Germany	No interests declared	
Martina Weise	Alternate	Germany	No restrictions applicable to this meeting	
Dimitrios Kouvelas	Member	Greece	No interests declared	
George Aislaitner	Alternate	Greece	No restrictions applicable to this meeting	
Agnes Gyurasics	Member	Hungary	No interests declared	
Melinda Sobor	Alternate	Hungary	No interests declared	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Kolbeinn Gudmundsson	Member	Iceland	No interests declared	
David Lyons	Member	Ireland	No restrictions applicable to this meeting	
Patrick Salmon	Alternate	Ireland	No interests declared	
Daniela Melchiorri	Member	Italy	No interests declared	
Juris Pokrotnieks	Member	Latvia	No restrictions applicable to this meeting	
Romaldas Mačiulaitis	Member	Lithuania	No restrictions applicable to this meeting	
Jacqueline Genoux-Hames	Member	Luxembourg	No interests declared	
John Joseph Borg	Member	Malta	No interests declared	
Helen Vella	Alternate	Malta	No interests declared	
Pieter de Graeff	Member	Netherlands	No interests declared	
Johann Lodewijk Hillege	Alternate	Netherlands	No interests declared	
Karsten Bruins Slot	Member	Norway	No interests declared	
Piotr Fiedor	Member	Poland	No interests declared	
Bruno Sepodes	Member	Portugal	No interests declared	
Dinah Duarte	Alternate	Portugal	No interests declared	
Nela Vilceanu	Member	Romania	No interests declared	
Jan Mazag	Member	Slovakia	No interests declared	
Ivana Pankuchova	Alternate	Slovakia	No interests declared	
Stanislav Primožič	Member	Slovenia	No interests declared	
Concepcion Prieto Yerro	Member	Spain	No interests declared	
Arantxa Sancho-Lopez	Alternate	Spain	No interests declared	
Kristina Dunder	Member	Sweden	No interests declared	
Filip Josephson	Alternate	Sweden	No interests declared	
Greg Markey	Member	United Kingdom	No interests declared	
Rafe Suvarna	Alternate	United Kingdom	No interests declared	
Robert James Hemmings	Co-opted member	United Kingdom	No restrictions applicable to this meeting	
Hubert Leufkens	Co-opted member	Netherlands	No interests declared	
Jan Mueller-Berghaus	Co-opted member	Germany	No interests declared	
Jean-Louis Robert	Co-opted member	Luxembourg	No interests declared	
Sol Ruiz	Co-opted member	Spain	No interests declared	
Christophe Focke	Expert - in person*	Belgium	No interests declared	
Sarah Goossens	Expert - in	Belgium	No interests declared	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
	person*			
Simona Skacelova	Expert - in person*	Czech Republic	No interests declared	
Anne Hasle Buur	Expert - in person*	Denmark	No interests declared	
Sinan B. Sarac	Expert - in person*	Denmark	No interests declared	
Sabine Mayrhofer	Expert - in person*	Germany	No interests declared	
Jorge Camarero Jiménez	Expert - in person*	Spain	No restrictions applicable to this meeting	
Maria Elisabeth Kalland	Expert - in person*	Norway	No restrictions applicable to this meeting	
Jan Sjöberg	Expert - in person*	Sweden	No interests declared	
Odoardo Maria Olimpieri	Expert - in person*	Italy	No restrictions applicable to this meeting	
Gwennaelle Even	Expert - in person*	France	No interests declared	
Giuseppe Rosano	Expert - in person*	Italy	No interests declared	
Shirley Hopper	Expert - in person*	United Kingdom	No interests declared	
Kofi Owusu	Expert - in person*	United Kingdom	No interests declared	
Marion Westwood	Expert - in person*	United Kingdom	No restrictions applicable to this meeting	
Eirini Apostolidou	Expert - in person*	Greece	No interests declared	
Maria Jesús Fernández Cortizo	Expert - via telephone*	Spain	No interests declared	
Krishna Prasad	Expert - via telephone*	United Kingdom	No restrictions applicable to this meeting	
Svein Rune Andersen	Expert - via telephone*	Norway	No interests declared	
Rune Kjeken	Expert - via telephone*	Norway	No restrictions applicable to this meeting	
Paolo Foggi	Expert - via telephone*	Italy	No interests declared	
Rutger de Vries	Expert - via telephone*	Netherlands	No interests declared	
Karina van Wonderen	Expert - via telephone*	Netherlands	No interests declared	
Patrick Vrijlandt	Expert - via telephone*	Netherlands	No interests declared	
Katalina Mettke	Expert - via telephone*	Germany	No interests declared	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Jan Schellens	Expert - via telephone*	Netherlands	No restrictions applicable to this meeting	
Ita Walsh	Expert - via telephone*	Netherlands	No interests declared	
Sigrid Klaar	Expert - via telephone*	Sweden	No interests declared	
Kristina Bech Jensen	Expert - via telephone*	Denmark	No interests declared	
A representative from the European Commission attended the meeting				
Meeting run with support from relevant EMA staff				

* Experts were only evaluated against the product(s) they have been invited to talk about.

17. Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

Oral explanations *(section 2)*

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

Initial applications *(section 3)*

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (**Day 180 List of outstanding issues**) and 3.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, **products in the decision making phase**.

Extension of marketing authorisations according to Annex I of Reg. 1234/2008 *(section 4)*

Extensions of marketing authorisations are applications for the change or addition of new strengths, formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

Type II variations - Extension of indication procedures *(section 5)*

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

Ancillary medicinal substances in medical devices *(section 6)*

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 *(section 3.5)*

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

Re-examination procedures *(section5.3)*

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

Withdrawal of application *(section 3.7)*

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) *(section 7)*

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

Pre-submission issues *(section 8)*

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

Post-authorisation issues *(section 9)*

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals

or type II variations to marketing authorisations that would require specific discussion at the plenary.

Referral procedures *(section 10)*

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found here.

Pharmacovigilance issues *(section 11)*

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

Inspections Issues *(section 12)*

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Innovation task force *(section 13)*

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found here.

Scientific advice working party (SAWP) *(section 14.3.1)*

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found here.

Satellite groups / other committees *(section 14.2)*

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmamacovigilance Risk Assessment Committee (PRAC).

Invented name issues *(section 14.3)*

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found here.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/